97 related articles for article (PubMed ID: 12035944)
1. Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man?
Ursing C; Härtter S; von Bahr C; Tybring G; Bertilsson L; Röjdmark S
J Endocrinol Invest; 2002 May; 25(5):459-62. PubMed ID: 12035944
[TBL] [Abstract][Full Text] [Related]
2. Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450(CYP)1A2.
Ursing C; Wikner J; Brismar K; Röjdmark S
J Endocrinol Invest; 2003 May; 26(5):403-6. PubMed ID: 12906366
[TBL] [Abstract][Full Text] [Related]
3. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.
Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L
Clin Pharmacol Ther; 2001 Jul; 70(1):10-6. PubMed ID: 11452239
[TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.
von Bahr C; Ursing C; Yasui N; Tybring G; Bertilsson L; Röjdmark S
Eur J Clin Pharmacol; 2000 May; 56(2):123-7. PubMed ID: 10877005
[TBL] [Abstract][Full Text] [Related]
5. Influence of cigarette smoking on melatonin levels in man.
Ursing C; von Bahr C; Brismar K; Röjdmark S
Eur J Clin Pharmacol; 2005 May; 61(3):197-201. PubMed ID: 15824912
[TBL] [Abstract][Full Text] [Related]
6. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.
Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW
Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842
[TBL] [Abstract][Full Text] [Related]
7. Calculation of Human Melatonin Partial Metabolic Clearance in Healthy Adult Volunteers for Investigation of a Novel in Vivo CYP1A2 Phenotyping Method: A Pilot Study.
Ohki S; Ogawa S; Takano H; Shimazaki H; Fukae M; Furihata T; Shibasaki H; Yokokawa A
Biol Pharm Bull; 2023; 46(5):736-740. PubMed ID: 37121701
[TBL] [Abstract][Full Text] [Related]
8. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.
Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I
Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790
[TBL] [Abstract][Full Text] [Related]
9. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats.
Wang X; Yeung JH
J Pharm Pharmacol; 2010 Aug; 62(8):1077-83. PubMed ID: 20663043
[TBL] [Abstract][Full Text] [Related]
10. Fibromyalgia--a syndrome associated with decreased nocturnal melatonin secretion.
Wikner J; Hirsch U; Wetterberg L; Röjdmark S
Clin Endocrinol (Oxf); 1998 Aug; 49(2):179-83. PubMed ID: 9828904
[TBL] [Abstract][Full Text] [Related]
11. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
[TBL] [Abstract][Full Text] [Related]
12. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
13. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
14. Impaired melatonin secretion in patients with Wernicke-Korsakoff syndrome.
Wikner J; Andersson DE; Wetterberg L; Röjdmark S
J Intern Med; 1995 Jun; 237(6):571-5. PubMed ID: 7782729
[TBL] [Abstract][Full Text] [Related]
15. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
[TBL] [Abstract][Full Text] [Related]
16. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2.
Buters JT; Tang BK; Pineau T; Gelboin HV; Kimura S; Gonzalez FJ
Pharmacogenetics; 1996 Aug; 6(4):291-6. PubMed ID: 8873215
[TBL] [Abstract][Full Text] [Related]
17. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Backman JT; Granfors MT; Neuvonen PJ
Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
[TBL] [Abstract][Full Text] [Related]
18. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism.
Hilli J; Korhonen T; Turpeinen M; Hokkanen J; Mattila S; Laine K
J Clin Pharmacol; 2008 Aug; 48(8):986-94. PubMed ID: 18490497
[TBL] [Abstract][Full Text] [Related]
19. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
20. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
